Applied DNA Sciences Inc (APDN) News
Filter APDN News Items
APDN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
APDN News Highlights
- APDN's 30 day story count now stands at 2.
- Over the past 7 days, the trend for APDN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DNA and MRNA are the most mentioned tickers in articles about APDN.
Latest APDN News From Around the Web
Below are the latest news stories about APPLIED DNA SCIENCES INC that investors may wish to consider to help them evaluate APDN as an investment opportunity.
Applied DNA Extends Application of Linea(TM) IVT Platform to saRNA (self-amplifying mRNA)- Extension Increases Total Addressable Market to Include Both Conventional Non-Amplifying mRNA and saRNA -- Extension Enabled by the Company's Ongoing Platform Development and Optimization -STONY BROOK, NY / ACCESSWIRE / November 16, 2023 / Applied ... |
Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea(TM) DNA Platform- Preclinical Orders for Additional Customers Underway -STONY BROOK, NY / ACCESSWIRE / November 9, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it has ... |
Applied DNA Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value AnimalsApplied DNA Sciences, Inc. (NASDAQ:APDN) (‘Applied DNA' or the "Company"), a leader in polymerase chain reaction ("PCR")-based technologies, and the Cornell University College of Veterinary Medicine ("CUCVM") today announced the signing of a sponsored research agreement (the "Agreement") for a translational research study to accelerate the development and optimization of the Company's LineaDNA™-lipid nano particle (LNP)-based veterinary |
Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP ProgramsApplied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the appointment of Beverly Wolgast, Ph.D., as executive director of Quality and cGMP Programs. |
Applied DNA Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation KitApplied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the general availability of Linea™ IVT platform evaluation kits (the "Kit") and the first shipment of a Kit to an existing Linea™ IVT Template customer. |
Applied DNA Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA ProductionApplied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the filing with the United States Patent and Trademark Office of two provisional patent applications claiming compositions of matter and methods to reduce or potentially eliminate double-stranded RNA (dsRNA) byproducts generated during the production of mRNA therapeutics. |
Applied DNA Reports Third Quarter Fiscal 2023 Financial Results and Provides Corporate UpdateApplied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for the third quarter of fiscal 2023 ended June 30, 2023. |
ADT (ADT) Q2 Earnings and Revenues Miss EstimatesADT (ADT) delivered earnings and revenue surprises of -30.43% and 2.88%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Applied DNA to Report Third Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, August 10, 2023Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release financial results for the three months ended June 30, 2023 after the market close on Thursday, August 10, 2023. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. |
3 Penny Stocks to Buy Before the BreakoutWhen it comes to penny stocks, you should do your research. |